Ultimately, these data confirm our screen findings that loss of Ifngr1, Jak2, or Stat1 sensitizes B-ALL cells to CAR-T therapy in vivo but promoted resistance in vitro. The gene discussed is IFNGR1; the disease is acute lymphoblastic leukemia.